english.prescrire.org > Prescrire International > N°234 - February 2022

n°234

February 2022

Issue Contents
Editorial

Free  Covid-19 vaccines: good for business too

p.31

Marketing Authorisations


Olaparib (Lynparza°) in combination with bevacizumab in ovarian cancer

p.33-35

Inset. Olaparib monotherapy in ovarian cancer after at least two lines of chemotherapy

p.34

Atezolizumab (Tecentriq°) + bevacizumab in certain hepatocellular carcinomas

p.35-36

Lumasiran (Oxlumo°) in primary hyperoxaluria type 1

p.36-37
As of 2021, still too little evaluation of its effect on clinical symptoms

Sofosbuvir (Sovaldi°), sofosbuvir + ledipasvir (Harvoni°) in chronic hepatitis C from 3 years of age

p.37-38

Sofosbuvir + velpatasvir (Epclusa°) in chronic hepatitis C in children from 6 years of age and in adolescents

p.38-39

Budesonide (Jorveza°) orodispersible tablets in eosinophilic oesophagitis

p.39

Ixekizumab (Taltz°) in axial spondyloarthritis

p.40-41

Upadacitinib (Rinvoq°) in "radiographic" axial spondyloarthritis

p.41

Secukinumab (Cosentyx°) in "non-radiographic" axial spondyloarthritis

p.41

Nasal naloxone 1.8 mg (Nyxoid°) in opioid overdose

p.42

Free  Rituximab (Mabthera° or other brands) in certain non-Hodgkin lymphomas in children

p.43

Adverse Effects


Update on myocarditis linked to the covid-19 messenger RNA vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°)

p.44-45

Flecainide: fatalities and cardiac arrests?

p.46-47

Immunostimulatory immune checkpoint inhibitors: toxic epidermal necrolysis and Stevens-Johnson syndrome

p.47

Pneumococcal vaccine errors: infants poorly protected

p.48-49

INN Common stem: ­-gliflozin

p.49

Outlook


Free  Towards better patient care: drugs to avoid in 2022

p.50-53

Inset. Main changes in the 2022 update

p.52

The need for double-blind randomised clinical trials in oncology

p.54

Conflicts of interest: insufficient transparency in Europe

p.54-55

A new European authority for health crises

p.55

Masthead


Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe